World's Initial Research Evaluating Multivalent Inactivated COVID-19 Vaccine Launches

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products, recently announced that the Chilean Public Health Institute approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31, 2022. 

This study is the world's first study researching multivalent inactivated COVID-19 vaccine.

The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac®, mRNA, or adenovirus vector COVID-19 vaccine.

Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC, said in a press release issued on September 6, 2022, "SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine."

"We are proud of the fact that CoronaVac® can protect individuals as young as six months of age, and this clinical approval will allow even better vaccine protection."

The CoronaVac vaccine has been used in more than 60 countries and regions worldwide.